Gilead‘s product sales fueled the significant increase in revenue and profit. Its total product sales for the fourth quarter of FY 2014 were $7.2 billion compared to $3 billion for the fourth quarter the year prior.
Driven by sales of hepatitis C drugs Sovaldi and Harvoni, Gilead’s antiviral product sales skyrocketed in the fourth quarter of 2014 to $6.7 billion, up from $2.6 billion for the same period of 2013.
More articles on healthcare finance:
CFO vs. CIO: Bridging the gap in perspective
10 pieces of advice hospital CFOs shared this month
5 CFOs in the headlines this week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.